Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24)

Affiliations

¹ AIMM Therapeutics, Amsterdam, the Netherlands.
² Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
³ School of Life Sciences, The University of Nottingham, Nottingham, UK; NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
⁴ Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
⁵ Public Health Service of Amsterdam, Amsterdam, the Netherlands; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
⁶ AIMM Therapeutics, Amsterdam, the Netherlands. Electronic address: tbeaumont@aimmtherapeutics.com.
⁷ Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: J.Schinkel@amc.uva.nl.

Published Erratum

Sabrina J Merat et al. J Hepatol. 2020 Oct.

. 2020 Oct;73(4):999-1000.

doi: 10.1016/j.jhep.2020.07.004. Epub 2020 Aug 1.

¹ AIMM Therapeutics, Amsterdam, the Netherlands.
² Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
³ School of Life Sciences, The University of Nottingham, Nottingham, UK; NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
⁴ Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
⁵ Public Health Service of Amsterdam, Amsterdam, the Netherlands; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
⁶ AIMM Therapeutics, Amsterdam, the Netherlands. Electronic address: tbeaumont@aimmtherapeutics.com.
⁷ Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: J.Schinkel@amc.uva.nl.

No abstract available

Erratum for

Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
Merat SJ, Bru C, van de Berg D, Molenkamp R, Tarr AW, Koekkoek S, Kootstra NA, Prins M, Ball JK, Bakker AQ, de Jong MD, Spits H, Beaumont T, Schinkel J. Merat SJ, et al. J Hepatol. 2019 Jul;71(1):14-24. doi: 10.1016/j.jhep.2019.02.013. Epub 2019 Feb 21. J Hepatol. 2019. PMID: 30797052